Analysts forecast that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post sales of $800,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Aclaris Therapeutics’ earnings. The lowest sales estimate is $600,000.00 and the highest is $1.00 million. The business is scheduled to report its next earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current year, with estimates ranging from $680,000.00 to $1.68 million. For the next year, analysts forecast that the firm will report sales of $23.55 million per share, with estimates ranging from $18.58 million to $28.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $2.00 million.

A number of brokerages have recently issued reports on ACRS. JMP Securities reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research cut shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $39.20.

Aclaris Therapeutics (ACRS) opened at $22.27 on Friday. Aclaris Therapeutics has a twelve month low of $21.47 and a twelve month high of $33.25.

Several institutional investors have recently made changes to their positions in ACRS. Eagle Asset Management Inc. boosted its stake in shares of Aclaris Therapeutics by 287.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock valued at $36,828,000 after purchasing an additional 1,007,343 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after purchasing an additional 697,104 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in Aclaris Therapeutics by 79.6% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock valued at $33,880,000 after buying an additional 553,752 shares during the period. FMR LLC boosted its position in Aclaris Therapeutics by 14.6% during the 2nd quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock valued at $51,425,000 after buying an additional 242,269 shares during the period. Finally, Nexthera Capital LP boosted its position in Aclaris Therapeutics by 204.9% during the 2nd quarter. Nexthera Capital LP now owns 340,000 shares of the biotechnology company’s stock valued at $9,221,000 after buying an additional 228,500 shares during the period. 92.10% of the stock is owned by institutional investors.

WARNING: “Analysts Anticipate Aclaris Therapeutics Inc (ACRS) Will Announce Quarterly Sales of $800,000.00” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/03/analysts-anticipate-aclaris-therapeutics-inc-acrs-will-announce-quarterly-sales-of-800000-00.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.